SERBP1 and cholangiocarcinoma: The analysis results showed that the expression values of SERBP1 were significantly higher in several cancers, including cervical squamous cell carcinoma (CESC), cholangiocarcinoma (CHOL), colon adenocarcinoma (COAD), lymphoid neoplasm, diffuse Large B-cell lymphoma (DLBC), glioblastoma multiforme (GBM), Brain lower grade glioma (LGG), pancreatic adenocarcinoma (PAAD), rectum adenocarcinoma (READ), stomach adenocarcinoma (STAD), thymoma (THYM), and uterine carcinosarcoma (UCS).